🚀 Avengers: Endgame re-release aims for $900M mark

Avengers: Endgame Encore is making a comeback to chase a major North American box office milestone. The film, starring Robert Downey Jr. and Chris Evans, is re-releasing in September to connect with Avengers: Doomsday. Currently, the movie has earned $858.4 million domestically. It needs roughly $42 million more to surpass the $900 million domestic target. This run could potentially push it to the top spot in North American box office rankings. 🎬

🎬 Khalifa nears top Mollywood hits in box office race

Prithviraj Sukumaran's Khalifa is performing steadily at the box office despite negative reviews and competition. The film has earned a net total of 17.74 crore in 9 days across 613 shows in India. Worldwide, Khalifa has grossed 39.93 crore, putting it at 9th among Mollywood films. It is close to surpassing Bharathanatyam 2 Mohiniyattam and is expected to beat Thudakkam by the second weekend. Achieving this will make Khalifa the 7th highest-grossing Mollywood film of 2026.

🚀 Lokesh Kanagaraj's DC hits massive 15x multiplier

The film DC, starring Lokesh Kanagaraj and Wamiqa Gabbi, achieved a massive 15x opening-day multiplier in the Indian box office. The movie is currently performing well, having crossed 50 crore net and is expected to reach 70 crore net. As of day 22, the Tamil romantic action thriller has earned a total of 67.87 crore net in India. It originally opened at 4.4 crore net, showing consistent performance over its run. The film is likely to conclude its run with an opening-day multiplier exceeding 16x. 🚀

🎬 Awarapan 2 cracks top 100 Bollywood grossers

Emraan Hashmi's Awarapan 2 has surpassed several major films at the worldwide box office. The action thriller achieved a worldwide gross of 211.24 crore in 15 days, with 151.84 crore net from India. This places it at the 96th spot globally, beating Don 2 and others. Currently, it is the 5th highest-grossing Bollywood film of 2026 globally. The film aims to surpass Ajay Devgn’s Dhamaal 4 next. 🎬

🚀 Akshay Kumar needs 68.96 Cr for big milestone

Akshay Kumar is aiming for a major post-COVID box office milestone with his upcoming film, Haiwaan. He has released 17 theatrical films since the pandemic started, with a total net collection of 1631.04 crore. To hit the 1700 crore mark, he requires just 68.96 crore from the new release. This goal follows his recent success with Welcome To The Jungle, which earned 137.93 crore. Fans will be watching closely to see if this target is achieved soon.

📉 Indian Bank Stocks Hit Decades-Long Price Gap

Indian bank stocks have recently displayed the widest exchange price gap in several decades. This significant fluctuation was observed across various major financial institutions operating within India. The specific data points detail the extreme price swings recorded during the recent trading sessions. This massive gap reflects broader shifts in investor sentiment and market dynamics within the banking sector. Analysts are now closely watching these trends to predict the future trajectory of the sector. 📉

🎬 Suriya's film sees huge jump in box office sales

Suriya's movie, Vishwanath And Sons, is performing strongly despite competition from films like Toxic. On the third Saturday, August 29, the film showed a massive 69% jump in ticket sales within just 4 hours. In total, the drama has already registered 2.76 million tickets on BMS across 14 days. This indicates strong word-of-mouth pulling in good footfalls for the movie. Suriya has surpassed 8 million ticket sales across his three major releases in 2026. 📈

🩺 Statin cuts CV risk in seniors, but no big life improvement

Atorvastatin reduced the risk of major cardiovascular events by 30% compared to placebo in adults aged 70 or older. The large STAREE trial was conducted in general practices across Australia, involving 9971 independently living adults. After a median follow-up of 5.9 years, the benefit was seen, though disability-free survival did not significantly improve. This research addresses the evidence gap for primary prevention in older adults, with results published in The New England Journal of Medicine. Further research is needed to understand this disconnect between event reduction and overall survival outcomes.

🔬 Milvexian trial fails to cut CV events after ACS

The Phase 3 LIBREXIA ACS trial did not show that adding milvexian reduced cardiovascular events following acute coronary syndrome (ACS). This study involved 14,194 patients across 44 countries, with final results presented at the ESC Congress 2026. CV death, MI, or stroke was 5.4% in the milvexian group versus 5.1% in the placebo group. Despite demonstrating expected anticoagulation, the drug failed to significantly lower MACE on top of standard antiplatelet therapy. Future trials, like LIBREXIA AF, are examining higher doses in different conditions. 🔬

🎬 Christopher Nolan's Odyssey Crushes Box Office Records

The Odyssey has surpassed its break-even point at the worldwide box office, making it a massive hit. The film, directed by Christopher Nolan, is performing strongly in cinemas globally. As of now, the worldwide total stands at $1.458 billion, with domestic gross at $549.5 million. Having a $250 million budget, the epic has earned approximately $833 million in profit over its break-even target. The film, released on July 17, is expected to continue dominating the box office for several more weeks. 🎬

🌟 Suriya's film hits big in Telugu states

Vishwanath And Sons has become the 5th highest-grossing Kollywood film in Telugu states. The movie, starring Suriya and Mamitha Baiju, earned a gross of 58.55 crore in the Telugu states over 15 days. This performance significantly boosted the film, which was underperforming in Tamil Nadu. The film had a breakeven target of around 40 crore gross and is expected to cross the 60 crore mark soon. It is also projected to overtake Enthiran for the 4th spot in the rankings. 🚀